Exosomes: product identity, evidence and regulatory questions
Products described as exosomes should not be treated as one established skin treatment.
Consultation information
On this page
What needs clarification first?
Clarify the exact product, route and purpose. A skin concern does not establish suitability. No local product, source, route or authorization is verified here; this page cannot establish a treatment recommendation. X1X2
| Proposal | What it describes | What must be clarified | Important limit | Question to ask |
|---|---|---|---|---|
| Exosome product | A product marketed under that name | Identity and evidence for the intended use | The name is not FDA approval | Which exact product and evidence? X1 |
| Microneedling combination | A device procedure with an accompanying substance | Evidence for the whole combination | Device authorization does not cover every substance | Has this combination been evaluated? R2 |
| Research participation | Use within a proposed study | Oversight, consent and product information | Research is not routine treatment approval | What review and safeguards apply? X2 |
These are different proposals, not interchangeable packages. Study or manufacturer registration and the word regenerative do not prove approval, effectiveness or suitability. Request documents for the actual product and country. X1X2
Which different proposals may be described?
Assessment can clarify the skin concern and suitable alternatives, including postponement. An unverified product is not an established option. Repair or rejuvenation claims need product-specific clinical support, not a scientific-sounding name. X1X2
These safety notices do not predict benefit, duration or session schedules for an unspecified aesthetic product, or settle local authorization. Claims about another material or application cannot establish the proposed use as safe. X1X2
What should be checked before deciding?
Request product identity, source, route, purpose and oversight. Ask what is known and unknown. Consent should not become a marketing form. X1
What is known about risks?
The FDA reported serious adverse events after unapproved products marketed as containing exosomes. Its broader regenerative-product warning also describes serious harms across different products. Those reports must not be presented as a measured complication rate for every aesthetic exosome product; uncertainty is not evidence of safety. X1X2
What if a product has already been used?
After use, retain the product name and available records and discuss symptoms with a clinician. Follow-up should address adverse effects and the original concern. Uncertainty or no benefit calls for reassessment, not automatic repetition. X1X2
Questions about exosomes
Are any exosome products FDA-approved?
The FDA notice accessed for this page says there are none. That statement concerns the United States and should be read with the notice's date and context. It is not a certificate about an individual product elsewhere. X1
Does the FDA notice determine the status in Türkiye?
No. The FDA explains that it does not oversee treatment in other countries. The specific product's status in Türkiye requires separate verification. This page does not assert a Turkish approval, ban or clinic authorization. X1X2
Does microneedling approval cover an accompanying product?
No. A device's authorization does not establish that applying another substance with it is safe or effective. Ask about evidence for the exact combination and route; combining two procedures does not transfer approval between them. R2
Does participation in research mean treatment is approved?
No. A research proposal requires its own review, consent and safeguards. Participation is not a promise of benefit or routine marketing authorization. Ask what is experimental and how concerns will be handled before considering enrolment. X1
Does this page confirm a treatment is available?
No. This page confirms neither stock nor an established service. Product identity, use, evidence and authorization require verification before individualized discussion. X1X2